OBJECTIVE The present study was undertaken to obtain data using the combination of SSc and lamivudine (LAM), entecavir (ETV) or telbivudine (LdT) in HepG2.2.15 cells to explore whether SSc acts as a potent adjuvant of nucleoside analogues in anti-HBV treatment. METHODS HepG2.2.15 cells were incubated with either SSc combined with any one of three nucleoside analogues (NAs) LAM, ETV, LdT or only one of them for 48 h. The expression profiles of HBV DNA, HBsAg, HBeAg, and HBcAg were examined by real-time quantitative PCR, ELISA, and western blot. RESULTS Compared with mono-drug treatment, the combination of SSc and any of the three nucleoside analogues significantly promoted additional reduction on HBV DNA level. Declined levels of HBsAg, HBeAg, and HBcAg were observed in SSc and LdT combination group. CONCLUSION These in vitro results indicated that SSc acted as a promising nucleoside analogue adjuvant, especially for telbivudine in the therapeutic strategies against HBV infection.

中文翻译：

---

saikosaponin c和telbivudine的组合可协同增强抗HBV活性。

目的进行本研究以获取SSc和拉米夫定（LAM），恩替卡韦（ETV）或替比夫定（LdT）在HepG2.2.15细胞中的组合数据，以探讨SSc是否可作为抗HBV核苷类似物的有效佐剂治疗。方法将HepG2.2.15细胞与SSc和三种核苷类似物（NAs）LAM，ETV，LdT或其中任一种一起孵育48小时。通过实时定量PCR，ELISA和western blot检查HBV DNA，HBsAg，HBeAg和HBcAg的表达情况。结果与单药治疗相比，SSc和三种核苷类似物的组合显着促进了HBV DNA水平的进一步降低。SSc和LdT组合组的HBsAg，HBeAg和HBcAg水平下降。